Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PhaseII, Open-Label, Multinational, Multi-Centre, Sequential Group, Dose-Escalation Study to Assess the Safety and Antiviral Activity of LB80380 for 12 Weeks in Patients With Lamivudine-Refractory Chronic Hepatitis B

NCT00895596 is registered in ClinicalTrials.gov with LG Life Sciences as lead sponsor.

NCT NCT00895596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00895596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PhaseII, Open-Label, Multinational, Multi-Centre, Sequential Group, Dose-Escalation Study to Assess the Safety and Antiviral Activity of LB80380 for 12 Weeks in Patients With Lamivudine-Refractory Chronic Hepatitis B
Lead sponsor
LG Life Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2004
Completion date
December 31, 2007
Enrollment
65 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b